DanielGale LondonUnited Kingdom

Daniel Gale trained at Cambridge University before moving to London for postgraduate training in Nephrology. Since 2018 he has held the St Peter’s Chair of Nephrology at University College London, where he leads the Centre for Genetics and Genomics in the Department of Renal Medicine. Professor Gale leads the North/Central London translational renal genetics service that has pioneered genomic testing and offers clinical trial involvement to patients and families with rare kidney diseases, including polycystic kidney disease, C3 glomerulopathy and Alport syndrome. He discovered (and identified the genetic basis of) the diseases HIF2α erythrocytosis with pulmonary hypertension, which results from defective oxygen sensing; and CFHR5 nephropathy, which is endemic in Cypriots. He chairs the Genomics England Therapeutic Innovation and Trials Research Network and helped develop the indications for genomic testing for kidney diseases within mainstream NHS care. His research group has conducted key large-scale genomics studies in numerous diseases. As director of the RaDaR registry (www.rarerenal.org) that includes over 35,000 patients recruited at >100 hospitals, his team has recently published clinical outcomes in 28 rare renal conditions, revealing the disproportionate impact these rare diseases have on the overall burden of kidney failure.